skip to Main Content

TreatSMA vigil on the decisive day

  • 23/10/2018

Today the entire SMA community is awaiting the outcome of the Committee meeting which is taking place at the National Institute of Health and Care Excellence in Manchester. The Committee is to decide whether spinal muscular atrophy will be treated on the NHS.

Read More

Avexis files for regulatory approval of gene therapy

  • 18/10/2018

Avexis has informed today that the company has submitted applications for regulatory approval of AVXS-101, the groundbreaking gene therapy product developed to treat spinal muscular atrophy.

Submissions have been filed with the European Medicines Agency, the US Food and Drug Administration, and the Japanese regulator.

Read More

Roche announces positive interim results of risdiplam trials

  • 03/10/2018

Roche today announced interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam as a treatment for spinal muscular atrophy. The data were presented yesterday at the 23rd International Annual Congress of the World Muscle Society in Mendoza, Argentina.

Read More

TreatSMA met with the Roche UK team

  • 03/10/2018

At the request from TreatSMA, on Monday 24 September five members of TreatSMA held a meeting with Roche in London. We discussed our advocacy work and general wider issues facing the SMA Community.

Read More
Back To Top
function mp_search() { ?>